A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart
Keywords: Bronchiectasis; Ciprofloxacin; Dry powder inhaler; Nanoparticles; Pseudomonas aeruginosa; AA; acetic acid; ASM; artificial sputum medium; Bc; basolateral compartment; CSat; saturation solubility of the native CIP; CF; cystic fibrosis; CFM; confocal fluore